Study #2023-0063
Phase 2 trial of Obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Obinutuzumab, CC-99282
Description
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Follicular Lymphoma, Tumor
Study phase:
Phase II
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.